Introduction
Endothelial cells (ECs) exert critical functions in maintaining homeostasis in the vascular system. Endothelial inflammation is a major contributor to endothelial dysfunction in cardiovascular disorders such as hypertension, diabetes and atherosclerosis (Davignon and Ganz, 2004) .
Interleukin-1β (IL-1β) is a key pro-inflammatory mediator involved in endothelial dysfunction and serves as a major atherogenic factor (Fearon and Fearon, 2008) . The production of active IL-1β is tightly controlled through the formation and activation of the inflammasome. The NLRP3 inflammasome, the best-characterized family member, is a multiprotein complex consisting of NLRP3, caspase-1 and the adaptor ASC (PYCARD). Activation of the NLRP3 inflammasome promotes the cleavage of caspase-1 and the maturation of IL-1β and IL-18.
Excessive activation of the NLRP3 inflammasome and the ensuing IL-1β secretion have recently emerged as central mechanisms in the pathogenesis of metabolic diseases including type II diabetes, obesity, and atherosclerosis (Mitroulis et al., 2010; Strowig et al., 2012) . Activation of NLRP3 in ECs, triggered by dyslipidemia, disturbed blood flow, and visfatin, may contribute to the development of atherosclerosis and restenosis (Xia et al., 2014; Xiao et al., 2013) .
Statins comprise a class of cholesterol-lowering drugs widely used in the treatment of hypercholesterolemia and coronary artery diseases (CAD). Acting as HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors, statins increase the expression of low-density lipoprotein (LDL) receptor in the liver, resulting in increased cholesterol uptake and lowering circulating cholesterol levels. In addition, statins have immunomodulatory and anti-inflammatory properties (Morimoto et al., 2006; Spyridopoulos et al., 2004) . Statins also improve endothelial function (Kesavan et al., 2014) . Recent studies have shown that statins This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on May 25, 2017 as DOI: 10.1124 at ASPET Journals on October 14, 2017 molpharm.aspetjournals.org Downloaded from affect the anti-NLRP3 in patients with cardiovascular disease. A randomized clinical study showed that atorvastatin markedly diminished NLRP3 inflammasome levels in CAD patients (Satoh et al., 2014) . In monocytic THP-1 cells, atorvastatin inhibited activation of the NLRP3 inflammasome (Satoh et al., 2014) . Rosuvastatin has been reported to alleviate diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and mitogen-activated protein kinase (MAPK) pathways in a rat model of type II diabetes (Luo et al., 2014) . However, the mechanisms by which statins regulate NLRP3 inflammasome remain largely unknown.
The nuclear pregnane X receptor (PXR; NR1I2) is a member of the nuclear receptor superfamily and functions as the key regulator of the body's defense against xenobiotics, including pollutants, drugs, dietary compounds, and their metabolites (Kliewer et al., 2002) . In addition to its conventional role in xenobiotic metabolism in liver and intestines, we and others also found that PXR is expressed in the vasculature where it regulates vascular detoxification and inflammation (Wang et al., 2013) . In particular, PXR suppresses the expression of pro-inflammatory adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and endothelial selectin (E-selectin) in response to TNF-α and lipopolysaccharide (LPS) in ECs. Overexpression of a constitutively active PXR in rat carotid arteries attenuated pro-inflammatory responses (Wang et al., 2013) . Notably, PXR appears to orchestrate the regulated expression of the key genes responsible for detoxification and innate immunity programs in ECs (Wang et al., 2014) . Statins have been known to activate PXRs (Howe et al., 2011) . Thus, we sought to investigate the effects of statins in activation of NLRP3 inflammasomes in ECs and the underlying mechanisms.
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Materials and Methods

Cells and Reagents
Human umbilical vein endothelial cells (HUVECs) were cultured in medium 199 containing heparin (0.1 mg/ml), acidic fibroblast growth factor (FGF) (10 ng/ml), L-glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 U/ml) and 20% FBS. Bovine aortic endothelial cells (BAECs) were maintained in Dulbecco's modified Eagle medium (DMEM) with 10% FBS, penicillin (100 U/ml), streptomycin (100 U/ml). Rifampicin was from Cayman (Ann Arbor, MI).
Antibodies against NLRP3 and NF-B p65 were from Abcam (Cambridge, UK). Antibody to caspase-1 was from Cell Signaling Technology (Danvers, MA). Antibodies against PXR, IBα, IgG, GADPH, Histone and β-actin were from Santa Cruz Biotechnology (Santa Cruz, CA).
Antibody against LOX-1 was from Sigma-Aldrich (St Louis, MO). Human recombinant TNF- was from R&D Systems (Minneapolis, MN). Reactive oxygen species (ROS) inhibitors (NAC and DPI) were from Sigma-Aldrich (St Louis, MO). Oxidized LDL (oxLDL) was from Yiyuan biotechnology (Guangzhou, China). Other reagents were from Sigma-Aldrich.
Quantitative Reverse Transcriptase-PCR (qRT-PCR)
Total RNA was isolated using Trizol (Invitrogen, Carlsbad, CA), then reverse transcribed into cDNA by using iScript cDNA synthesis kit (Bio-rad, Hercules, CA). qRT-PCR was performed by using SYBR Green Supermixes (Bio-rad) and a 7500 Real-time PCR machine (Applied Biosystems, Foster City, CA). Fold changes of gene expression were calculated using the 2 -ΔΔCt method. The qRT-PCR primers used were as follows: NLRP3 forward primer:
5'-CTTCTCTGATGAGGCCCAAG-3', reverse primer:
5'-GCAGCAAACTGGAAAGGAAG-3'; LOX-1 forward primer:
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GAPDH was used as an internal control.
Western blotting
Total protein was extracted from cells with lysis buffer (10 mM Tris· HCl at pH 7.4, 150 mM NaCl, 0.1% Triton X-100) supplemented with a protease inhibitor cocktail (Roche Diagnostics).
Cytoplasmic proteins were extracted with hypotonic lysis buffer (10 mM Tris· HCl, pH 7.5, 1.5 mM MgCl2, 10 mM KCl, 0.5% Nonidet P-40). Nuclear proteins were extracted with high-salt buffer (20 mM Tris· HCl, 1.5 mM MgCl2, 420 mM NaCl, 10% glycerol, 0.2 mM EGTA). BCA protein assay reagents (Pierce, Rockford, USA) were used to assess protein concentration.
Protein samples were separated on SDS-PAGE and transferred onto PVDF membrane.
Immunoblotting was performed with primary antibodies and appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies, visualized using the ECL chemoluminescence system.
Adenoviral vectors and infection
Recombinant adenoviruses encoding VP-PXR (Ad-VP-PXR), Ad-tTA (an adenovirus expressing tTA, a tetracycline-responsive transactivator), Ad-LacZ (β-galactosidase), and Ad-IBα were as previously described (Wang et al., 2013) . HUVECs were co-infected with Ad-tTA and Ad-VP-PXR in the presence or absence of tetracycline (0.1 g/ml).
This article has not been copyedited and formatted. The final version may differ from this version. 5'-GGUCUUCAGUUUCUUUACUTT-3'; antisense: 5'-AGUAAAGAAACUGAAGACCTT-3') or scrambled siRNA (sense: 5'-CGGGUUGCCCAAAGACGACAA-3'; antisense:
5'-UUGUCGUCUUUGGGCAACCCG-3') with Lipofectamine 2000 (Invitrogen). Experiments were performed with these cells at 24 h after transfection.
Chromatin Immunoprecipitation (ChIP) Assay
HUVECs were treated with 1% formaldehyde for DNA-protein crosslinking and then chromatin was sheared by sonication (3 times  15 seconds). Immunoprecipitations were performed with the use of a rabbit polyclonal antibody against NF-B/p65 or control IgG, and protein A/G Sepharose beads. After washing, the beads were eluted in elution buffer (1% SDS, 100 mM NaHCO3). DNA samples were extracted and purified after proteinase K digestion. The bound DNAs were amplified using qPCR with primers flanking the NF-B binding sites in the human NLRP3 promoter regions (Table 1 ). Relative DNA binding was expressed as fold enrichment compared to immunoprecipitates using control IgG (Fan et al., 2008) .
Plasmids and Transfection
The genomic fragment harboring -2977 to +151 bp in relation to transcription start site (Anderson et al., 2008) of human NLRP3 gene was cloned using PCR from the genomic DNA.
The primer sequences were 5'-CGGGCTAGCGGTCATACGGTAGTTCTA-3' (forward) and 5'-CGGCTCGAGGCCAGAAGAAATTCCTAG-3' (reverse). The amplified product was This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Effects of statins on oxLDL-or TNFα-induced NLRP3 inflammasome activation in ECs.
OxLDL and TNFα are critical atherogenic mediators known to induce the expression of pro-inflammatory genes in ECs (Yokode, 2001; Zhang et al., 2009) . To test the effects of oxLDL and TNF-α on the NLRP3 inflammasome in ECs, we treated HUVECs with various concentrations of oxLDL (0 ~ 200 g/ml) or TNFα (0 ~ 10 ng/ml) for 12 h. Western blotting showed that both oxLDL and TNFα dose-dependently increased the protein levels of NLRP3 and cleaved caspase-1 (Fig. 1A) . A similar dose-dependent action was observed at the NLRP3 mRNA level as measured by using qRT-PCR (Fig. 1B) . Next, we examined the effects of statins on NLRP3 inflammasome activation. We treated HUVECs with simvastatin (0.5 M) or mevastatin (5M) for 12 h before exposure to oxLDL or TNFα. As shown in Figure 1C , simvastatin or mevastatin significantly inhibited the oxLDL-or TNFα-induced increases in protein levels of NLRP3 and cleaved caspase-1. The mRNA level of NLRP3 was also decreased by the statins (Fig. 1D ). Taken together, these results indicated that statins attenuate the activation of NLRP3 inflammasome induced by oxLDL or TNFα in ECs.
Role of PXR in the suppressive effect of statins on oxLDL-or TNFα-activated NLRP3 inflammasome in ECs.
Statins have been reported to activate PXR in liver cells (Hoffart et al., 2012; Howe et al., 2011; Plee-Gautier et al., 2012) . Thus, we examined the effect of statins on PXR in ECs. We co-transfected pCMX-PXR and PXRE-Luc into BAECs, and then treated with atorvastatin, mevastatin or simvastatin at various concentrations for 24 h. PXR reporter activity was significantly increased by all three statins ( Fig. 2A) . In HUVECs, simvastatin and mevastatin This article has not been copyedited and formatted. The final version may differ from this version. 
Effects of PXR agonists on oxLDL-or TNFα-induced NLRP3 inflammasome.
To examine whether other specific PXR agonists have a similar inhibitory effect on NLRP3
inflammasome activation, we pretreated ECs with rifampicin (10 µM) or SR12813 (1 µM) before exposure to oxLDL or TNFα. As shown in Fig. 3A , rifampicin and SR12813 both inhbited the oxLDL-or TNFα-stimulated increases in NLRP3 and cleaved caspase-1. The mRNA level of NLRP3 was also decreased (Fig. 3B ). To rule out potential off-target effect of individual agonists, we infected HUVECs with Ad-VP-PXR. We found that overexpression of PXR attenuated the NLRP3 inflammasome activation in response to oxLDL or TNFα (Fig. 3C ).
Furthermore, PXR knockdown abrogated the suppressive effect of rifampicin on oxLDL-induced NLRP3 inflammasome activation ( Fig. 3D and E). Taken together, these results suggested that PXR agonists inhibit oxLDL-or TNFα-activated NLRP3 inflammasome in a PXR-dependent manner in ECs.
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To investigate whether statins attenuate NLRP3 inflammasome activation by inhibiting the LOX-1/NF-B pathway, we pretreated ECs with statins for 12 h before stimulation with ox-LDL.
As shown in Figures 5A LOX-1 activation results in the excessive generation of reactive oxygen species (ROS), which are known to trigger the activation of the NLRP3 inflammaosme (Schroder and Tschopp, 2010).
We found that simvastatin or mevastatin significantly reduced ROS generation in response to TNFα (supplemental Fig. 2) . Furthermore, the PXR agonists rifampicin and SR12813 also decreased NF-B activation by oxLDL or TNFα (supplemental Fig. 3 ). Thus, these results suggested that PXR inhibition of ROS may contribute to the inhibitory effects of statins on activation of the LOX-1/NF-B pathway and the NLRP3 inflammasome.
Effects of statins on PXR inhibition of NF-B binding to the NLRP3 promoter.
Since NF-B plays a central role in the transcriptional regulation of the NLRP3 gene, and PXR suppressed activation of NF-B target genes (Gu et al., 2006; Qiao et al., 2012; Xie and Tian, 2006) , we examined the effects of statin-activated PXR on NF-B binding activity to the human NLRP3 promoter. Bioinformatics analysis using the transcription element search system (TESS, http://www.cbil.upenn.edu/cgi-bin/tess/te) revealed 3 canonical NF-B-responsive elements in the 5′-flanking region of the human NLRP3 gene (Fig. 6A ). ChIP assays demonstrated that both oxLDL and TNFα increased NF-B binding at these motifs, and that these responses were inhibited by mevasatin (Fig. 6B) or SR12813 (Fig. 6C) . Furthermore, we performed the NLRP3 promoter reporter assay in BAECs. As shown in Figure 6D , TNFα increased the NLRP3-Luciferase reporter activity, which was inhibited by SR12813. These results indicated
Discussion
In this study, we demonstrated for the first time that statins can inhibit ox-LDL or TNF-α-induced NLRP3 inflammasome activation in ECs, and that this inhibitory effect is mediated by activation of the xenobiotic nuclear receptor PXR.
A variety of intracellular and extracellular stimuli have been known to trigger the activation of inflammasome activation (Fig 1) .
One of the important findings in this study is that PXR plays a critical role in the suppression of
TNF-and oxLDL-induced NLRP3 inflammasome activation in human ECs. This notion is
This article has not been copyedited and formatted. The final version may differ from this version. Fig. 2A-B) ; 2) Gene silencing of PXR abrogated the suppressive effect of statin on NLRP3 inflammasome (Fig. 2C-D) , whereas PXR agonists or overexpression of PXR elicited similar effects (Fig. 3A-C) . It is worth noting that the pharmacologic actions of PXR are highly divergent across species (Zhou et al., 2009 ).
The species divergence may be explained by the low homology in the ligand-binding domain , 2014) . We found that LOX-1 was essential for oxLDL-triggered NLRP3 inflammasome activation in ECs (Fig. 4A-B) . Activation of LOX-1 by oxLDL triggers the NFB signaling pathway (Matsunaga et al., 2003; Mattaliano et al., 2009 ). Here, we demonstrated that the PXR activation either by statins or rifampicin treatment, or by PXR overexpression, inhibited LOX-1 expression (Fig 5A-D) . Conversely, knockdown of PXR diminished the inhibitory effects of statins and rifampicin on LOX-1 (Fig 5E-H) , indicating that statins inhibit LOX-1 expression in a PXR-dependent manner. These results suggest that inhibition of LOX-1/NFB is a key mechanism by which statin/PXR signaling inhibits oxLDLThis article has not been copyedited and formatted. The final version may differ from this version. or TNFα-induced NLRP3 inflammasome activation in ECs (Fig. 4C-D) . This finding is consistent with the previously described reciprocal inhibition between PXR and NFB pathways In conclusion, our results demonstrate that statins inhibit NLRP3 inflammasome via PXR activation in ECs. Since the conversion of endothelium to a pro-inflammatory state is an early step in atherogenesis, the suppressive role of statins on endothelial inflammasome activation may provide new molecular insights into their pharmacological actions in the primary prevention of cardiovascular morbidity and mortality.
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